Marybeth Nelson

1.1k total citations · 1 hit paper
17 papers, 790 citations indexed

About

Marybeth Nelson is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Marybeth Nelson has authored 17 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 8 papers in Pathology and Forensic Medicine and 8 papers in Hematology. Recurrent topics in Marybeth Nelson's work include Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Marybeth Nelson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (7 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Marybeth Nelson collaborates with scholars based in United States, France and Australia. Marybeth Nelson's co-authors include Martín C. Mihm, Frank G. Haluska, F. Stephen Hodi, David B. Lautz, Nikhil H. Ramaiya, Sara E. Russell, Teresa C. Chen, Andrea Kruse, Alan J. Korman and Glenn Dranoff and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Marybeth Nelson

17 papers receiving 781 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 488 citations F. Stephen Hodi, Marcus O. Butler et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marybeth Nelson United States	7	487	438	243	209	126	17	790
Sanne H. Tonino Netherlands	18	375 0.8×	513 1.2×	521 2.1×	467 2.2×	158 1.3×	48	987
Marco Fangazio Italy	10	220 0.5×	273 0.6×	346 1.4×	483 2.3×	219 1.7×	20	727
Andreas Draube Germany	14	501 1.0×	413 0.9×	94 0.4×	106 0.5×	215 1.7×	30	807
Simar Pal Singh Netherlands	9	337 0.7×	192 0.4×	387 1.6×	235 1.1×	226 1.8×	14	793
Matthew Ku Australia	12	184 0.4×	526 1.2×	262 1.1×	531 2.5×	97 0.8×	47	821
Finlay MacDougall United Kingdom	7	302 0.6×	352 0.8×	166 0.7×	374 1.8×	104 0.8×	13	680
Emanuele Cencini Italy	13	218 0.4×	164 0.4×	262 1.1×	281 1.3×	108 0.9×	55	535
Antonis Dagklis Italy	15	411 0.8×	150 0.3×	511 2.1×	443 2.1×	230 1.8×	25	866
PM Kluin Netherlands	9	214 0.4×	355 0.8×	372 1.5×	539 2.6×	254 2.0×	15	973
Agnès Daudignon France	13	174 0.4×	130 0.3×	375 1.5×	290 1.4×	195 1.5×	38	687

Countries citing papers authored by Marybeth Nelson

Since Specialization

Citations

This map shows the geographic impact of Marybeth Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marybeth Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marybeth Nelson more than expected).

Fields of papers citing papers by Marybeth Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marybeth Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marybeth Nelson. The network helps show where Marybeth Nelson may publish in the future.

Co-authorship network of co-authors of Marybeth Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of Marybeth Nelson. A scholar is included among the top collaborators of Marybeth Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marybeth Nelson. Marybeth Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Leduc, Renee, Marybeth Nelson, Amy Sam, et al.. (2009). A573 Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma & Myeloma. 9. S86–S86. 1 indexed citations

Schlossman, R, Stacey Chuma, Renee Leduc, et al.. (2009). A535 Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Lymphoma & Myeloma. 9. S83–S84. 1 indexed citations

Treon, Steven P., Leukothea Ioakimidis, Jacob D. Soumerai, et al.. (2009). Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. Journal of Clinical Oncology. 27(23). 3830–3835. 187 indexed citations

Wagner, Lars M., John P. Perentesis, Joel M. Reid, et al.. (2009). Phase I trial and pharmacokinetic study of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with refractory solid tumors: A Children's Oncology Group Phase I Consortium study. Journal of Clinical Oncology. 27(15_suppl). 10017–10017. 3 indexed citations

Leleu, Xavier, Edie Weller, Aldo M. Roccaro, et al.. (2008). Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leukemia & lymphoma. 49(6). 1104–1107. 37 indexed citations

Hodi, F. Stephen, Marcus O. Butler, Darryl A. Oble, et al.. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences. 105(8). 3005–3010. 488 indexed citations breakdown →

Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2008). Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).. Blood. 112(11). 1010–1010. 2 indexed citations

Ghobrial, Irene M., Jeffrey Matous, Swaminathan P. Iyer, et al.. (2008). Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. Blood. 112(11). 832–832. 4 indexed citations

Ghobrial, Irene M., Stacey Chuma, Amy Sam, et al.. (2008). Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. Blood. 112(11). 1011–1011. 6 indexed citations

10.

Ghobrial, Irene M., Nikhil C. Munshi, Robert Schlossman, et al.. (2008). Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Blood. 112(11). 3696–3696. 11 indexed citations

11.

Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2008). Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). Journal of Clinical Oncology. 26(15_suppl). 8546–8546. 9 indexed citations

12.

Leleu, Xavier, Evdoxia Hatjiharissi, Aldo M. Roccaro, et al.. (2007). Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).. Blood. 110(11). 1486–1486. 1 indexed citations

13.

Soumerai, Jacob D., Kelly O’Connor, Christopher J. Patterson, et al.. (2007). Imatinib Mesylate (Gleevec®) Produces Responses in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia.. Blood. 110(11). 2575–2575. 3 indexed citations

14.

Ghobrial, Irene M., Xavier Leleu, Nancy Rubin, et al.. (2007). Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4493–4493. 1 indexed citations

15.

Ghobrial, Irene M., Renee Leduc, Marybeth Nelson, et al.. (2007). Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4496–4496. 3 indexed citations

16.

Ghobrial, Irene M., Swaminathan P. Iyer, Ashraf Badros, et al.. (2007). Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood. 110(11). 4494–4494. 5 indexed citations

17.

Manolios, Nicholas, Leslie Schrieber, Marybeth Nelson, & Carolyn L. Geczy. (1989). Enhanced interferon-gamma (IFN) production by lymph node cells from autoimmune (MRL/1, MRL/n) mice.. PubMed. 76(2). 301–6. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact